Beijing Co-CRO Medical Development

Beijing Co-CRO Medical Development is a specialized Contract Research Organization (CRO) based in Beijing, China, founded in 2002. The company provides comprehensive clinical research services for innovative drugs, biological products, and medical devices, spanning Phase I through IV clinical trials. Co-CRO is particularly recognized for its expertise in the anti-infective therapeutic area, having played a pivotal role in the clinical development of China's first long-acting HIV-1 fusion inhibitor, Albuvirtide (Aikening). Their service offerings include clinical development strategy, medical affairs, clinical operations, regulatory affairs, and Site Management Organization (SMO) services. The company has successfully supported the approval of multiple innovative drugs and traditional Chinese medicines by navigating the complex Chinese regulatory environment.